Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Point Sur Investors LLC (PSI) is an independent, privately held investment advisor located in Palo Alto, California. Founded in 2015, PSI has carved a niche in the biotech sector, particularly in long-biased investments targeting small to mid-cap US-based publicly traded biopharmaceutical companies. The firm is managed by a team of executives with extensive experience in biotech drug discovery, development, and commercialization, which enhances their ability to identify promising investment opportunities.
PSI's investment strategy is primarily focused on companies that are advancing medicines through human clinical trials. The firm aims to leverage its expertise to navigate the complexities of drug development and commercialization, thereby contributing to the advancement of patient care. Although PSI primarily engages in public equity investments, it also participates in late-stage private rounds, particularly in crossover investments, such as its involvement in Biomea Fusion's $56 million Series A financing.
Point Sur Investors concentrates its investment strategy on the biotech sector, specifically targeting small to mid-sized publicly traded biopharmaceutical companies. The firm typically invests in companies that are developing innovative therapies with the potential to significantly improve patient care. PSI's focus includes engaging in public equity investments while also participating in late-stage private rounds, particularly in crossover investments.
The firm seeks to identify companies that are advancing medicines through human clinical trials, emphasizing the importance of data-driven investment strategies. PSI's team, composed of biotech operators and scientists, enhances their investment approach by providing strategic insights and support to portfolio companies. This expertise is crucial in guiding companies through the complexities of drug development and commercialization.
Point Sur Investors has made notable investments in several biotech companies, reflecting its focus on innovative therapies. Key portfolio activity includes:
These investments highlight Point Sur Investors' strategy of backing companies that are not only publicly traded but also engaged in significant clinical advancements, aligning with their thesis of improving patient care through innovative therapies.
Management Team
Point Sur Investors is managed by a small group of executives with extensive experience in the biotech sector. While specific names and backgrounds are not disclosed, the team comprises individuals with a strong track record in drug discovery, development, and commercialization. Their expertise is instrumental in guiding the firm's investment strategies and supporting portfolio companies.
To pitch Point Sur Investors, founders should reach out via email at info@pointsurinvestors.com. It is recommended to include a comprehensive pitch deck that outlines the company's mission, clinical advancements, market potential, and team expertise. Founders should expect a response within a reasonable timeframe, although specific timelines are not disclosed.
Warm introductions are preferred, as they can enhance the likelihood of a favorable review. Clear and concise communication of the company's value proposition and alignment with PSI's investment focus is crucial for capturing the firm's interest.
As of April 2023, Point Sur Investors has been active in the biotech investment space, particularly with its participation in Biomea Fusion's $56 million Series A financing. This investment highlights the firm's commitment to supporting companies that are advancing innovative therapies. Additionally, PSI has disclosed recent acquisitions of shares in Dyne Therapeutics and PTC Therapeutics, further emphasizing its focus on companies with promising clinical advancements.
What are Point Sur Investors' investment criteria?
Point Sur Investors focuses on small to mid-cap publicly traded biopharmaceutical companies that are developing innovative therapies. The firm looks for companies that have entered human clinical trials and demonstrate the potential to significantly advance standard care.
How can founders pitch to Point Sur Investors?
Founders can reach out to Point Sur Investors via email at info@pointsurinvestors.com. It is advisable to include a detailed overview of the company, its clinical advancements, and how it aligns with PSI's investment focus.
What makes Point Sur Investors different from other investors?
Point Sur Investors distinguishes itself through its exclusive focus on the biotech sector and its team of experienced biotech operators and scientists. This expertise allows them to provide strategic insights and support to portfolio companies, enhancing their chances of success in drug development.
What is the geographic focus of Point Sur Investors?
The firm primarily invests in North America, concentrating on US-based publicly traded biopharmaceutical companies.
What is the typical check size for investments?
While specific check sizes are not disclosed, Point Sur Investors typically engages in public equity investments and late-stage private rounds, indicating a flexible approach to funding based on the opportunity.
What kind of post-investment involvement does Point Sur Investors have?
Point Sur Investors adds value to its portfolio companies through strategic insights and support from its experienced management team, guiding them through the complexities of drug development and commercialization.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.